Solutions for Plastic Surgery
Advanced Placental-Based Allografts When Patients Need It Most
Protective Barrier and Environment
- A semi-permeable protective barrier and environment that supports the healing cascade
- Protects the wound bed to aid in the development of granulation tissue
- Provides a human biocompatible extracellular matrix
Retains Regulatory Proteins
Contains 250+ regulatory proteins1-4
Product Advantages
- SMR2T™ Technology and patented PURION processing
- Terminally sterilized for additional level of safety
- Easy to apply
- Room temperature storage
- 5-year shelf life
- Compatible with negative pressure wound therapy (NPWT) and hyperbaric oxygen therapy (HBO)
Potential Clinical Use Examples
- Acute and Chronic Wounds
- Debridements
- Exposed bone and tendon
- Dehiscence
- Decubitus ulcers
- Flaps
- Bridge to STSG
- Limb salvage
- Other cases are possible
Case Examples
Case Study 1:
Challenge
62-year-old obese male, BMI of 29, type II diabetes, with a history of hypertension, myocardial infarction with stent placements, multiple abdominal surgeries, and over forty years of cigarette smoking, underwent large ventral hernia repair. At one week postop, the patient developed ischemia at the incision line, which led to an incisional dehiscence.
Studies have shown a direct correlation between the number of comorbidities and clinical outcomes. A significant rise in complications, length of stay, and mortality rates is associated with the rise in number of patient comorbidities.5-7
Surgical Intervention
The patient was managed with serial debridement and wet-to-dry dressings for two months, then placed on negative pressure wound therapy (NPWT) for four weeks at home. After one month of NPWT, the wound had only decreased by 30%. NPWT was discontinued, and dHACM (dehydrated Human Amnion/Chorion Membrane) was applied every other week, instead of weekly, due to the travel distance for the patient. The product provides a semi-permeable barrier that supports the healing cascade and protects the wound bed to aid in the development of granulation tissue in acute and chronic closures. It provides a biocompatible human extracellular matrix and retains 300+ regulatory proteins.1-3
Follow-Up
Upon examination at his two month follow-up visit, the wound was fully closed and re-epithelialized. The patient returned for a routine one-year visit and has remained fully closed and asymptomatic.
Case Study 2:
Clinical History
Patient presented with keloid after Caesarean section procedure.
Treatment
One third of the keloid scar was treated with dHACM (dehydrated Human Amnion/Chorion Membrane) in revision surgery to evaluate its outcome prior to treating the remainder of the scar. dHACM was placed within the incision site before suturing.
dHACM provides a semi-permeable barrier that supports the healing cascade and protects the wound bed to aid in the development of granulation tissue in acute and chronic closures. It provides a biocompatible human extracellular matrix and retains 300+ regulatory proteins.1-3
Follow-Up
The scar was greatly reduced in height and in color. Subsequent revision surgery treated the remainder of the keloid scar with dHACM.
Product Details
AMNIOFIX and AMNIOCORD are processed using the PURION process, a unique, patented method for placental-based allografts that is in accordance with the American Association of Tissue Banks (AATB) standards. The products are derived from healthy placental-tissue via Cesarean sections from live births in the US. The products undergo active preservation of the extracellular matrix (ECM) and regulatory proteins. Blood contaminants are removed via a proprietary cleansing process. For an additional level of safety, the products are terminally sterilized.
1. Koob TJ, Lim JJ, Massee M, Zabek N, Denozière G. Properties of dehydrated human amnion/chorion composite grafts: Implications for wound repair and soft tissue regeneration. J Biomed Mater Res B Appl Biomater. 2014;102(6):1353-1362. 2. Lei J, Priddy LB, Lim JJ, Massee M, Koob TJ. Identification of Extracellular Matrix Components and Biological Factors in Micronized Dehydrated Human Amnion/Chorion Membrane. Adv Wound Care (New Rochelle). 2017;6(2):43-53. 3. MM-RD-00086, Proteome Characterization of Purion Processed Dehydrated Human Amnion Chorion Membrane (dHACM) and Purion Plus Processed Dehydrated Human Umbilical Cord (dHUC) Allografts. 4. Bullard JD, Lei J, Lim JJ, Massee M, Fallon AM, Koob TJ. Evaluation of dehydrated human umbilical cord biological properties for wound care and soft tissue healing. J Biomed Mater Res B Appl Biomater. 2019;107(4):1035-1046. 5. Thombs BD, Singh VA, Halonen J, Diallo A, Milner SM. The effects of preexisting medical comorbidities on mortality and length of hospital stay in acute burn injury: evidence from a national sample of 31,338 adult patients. Ann Surg. 2007;245(4):629-634. 6. Myles PS, Iacono GA, Hunt JO, et al. Risk of respiratory complications and wound infection in patients undergoing ambulatory surgery: smokers versus nonsmokers. Anesthesiology. 2002;97(4):842-847. 7. Dunne JR, Malone DL, Tracy JK, Napolitano LM. Abdominal wall hernias: risk factors for infection and resource utilization. J Surg Res. 2003;111(1):78-84.
WEB107.001